Company record · QNCX · Biological Products, (No Diagnostic Substances)
IRulya Therapeutics Inc.
IRulya Therapeutics Inc.'s chief financial officer on the record is John Militello, effective not stated in the source, per the filing record.
The record holds 1 verified CFO change for IRulya Therapeutics Inc. from Form 8-K filings, filed July 31, 2026 and the CFO signature on its 10-K filed April 10, 2026.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | John Militello |
| Title as printed | Chief Financial Officer |
| Basis | Latest move: appointment, 8-K filed July 31, 2026 |
Seat timeline
2Every verified record for this seat, newest first, dated as the filing states it.
2026-07-31Appointment
Quince Therapeutics, Inc. appoints John Militello as CFOeffective date not stated in the filing · 8-K filed July 31, 2026 · sec.gov, Item 5.02
2026-04-1010-K signature
Brendan Hannah signed the annual report as Chief Business Officer and Chief Operating Officer and Chief Compliance Officer (Principal Financial Officer and Principal Accounting Officer)
10-K filed April 10, 2026 · sec.gov
“/s/ Brendan Hannah Chief Business Officer and Chief Operating Officer and Chief Compliance Officer April 10, 2026 Brendan Hannah (Principal Financial Officer and Principal Accounting Officer)”
Company
| Ticker | QNCX |
|---|---|
| SEC CIK | 0001662774 |
| Industry (SIC) | Biological Products, (No Diagnostic Substances) (2836) |
| Roster note | The DEF 14A filed 2026-08-25 also names Brendan Hannah alongside a Chief Financial Officer title. An 8-K with Item 5.02 was filed on 2026-10-09, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
8Other companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
Allogene Therapeutics, Inc.ALLO
Change disclosed, effective November 6, 2026
Armata Pharmaceuticals, Inc.ARMP
CFO: David House · effective July 17, 2026
Atara Biotherapeutics, Inc.ATRA
Interim CFO: Kevin G. Sarney · effective June 26, 2026
Caribou Biosciences, Inc.CRBU
Departure disclosed · Sriram Ryali · no successor on the record yet
ImageneBio, Inc.IMA
CFO: Yanina Grant-Huerta · effective July 20, 2026
Jasper Therapeutics, Inc.JSPR
Interim CFO: Jeet Mahal · effective October 9, 2026
Kalaris Therapeutics, Inc.KLRS
CFO: Liisa Bayko · effective July 20, 2026
Precision BioSciences, Inc.DTIL
CFO: Naresh Tanna · effective August 1, 2026
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.